- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06535659
VitaFlow LIBERTY Europe
VitaFlow Liberty™ Transkateter aortaklaffsystem Klinisk oppfølgingsstudie etter markedsføring
This is a prospective, single-arm, multi-center, observational, post-market clinical investigation to document the clinical safety and performance of MicroPort CardioFlow VitaFlow Liberty™ Transcatheter Aortic Valve System in the routine practice for the treatment of severe aortic valve stenosis. The primary endpoint is the composite rate of all-cause mortality and stroke with disability at 12 months.
Patients will receive transcatheter aortic valve replacement and examinations at the screening, procedure, discharge, and follow-up per local standard of care.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Zhujun Cai, PhD
- Telefonnummer: 86-021-38954600
- E-post: zjcai@microport.com
Studer Kontakt Backup
- Navn: Yann Poezevara, PhD
- Telefonnummer: 0033-146013409
- E-post: Yann.Poezevara@cf.microport.com
Studiesteder
-
-
-
Galway, Irland
- Rekruttering
- Galway University Hospital
-
Ta kontakt med:
- Darren Mylotte, MD
-
-
-
-
-
Castel Volturno, Italia
- Rekruttering
- Pineta Grande Hospital
-
Ta kontakt med:
- Alberto Morello
- Telefonnummer: +393397904191
- E-post: albertomorello83@gmail.com
-
Pisa, Italia
- Rekruttering
- Ospedale Cisanello
-
Ta kontakt med:
- Dr.Marco De Carlo
- Telefonnummer: +39 050 971 9530
- E-post: urp@ao-pisa.toscana.it
-
Potenza, Italia
- Rekruttering
- Azienda Ospedaliera Regionale -S.Carlo
-
Ta kontakt med:
- Eugenio Stabile
- Telefonnummer: +39 81 746 2228/53
- E-post: eugeniostabile@gmail.com
-
-
-
-
-
Carnaxide, Portugal
- Rekruttering
- Hospital de Santa Cruz
-
Ta kontakt med:
- Rui Teles
- Telefonnummer: +351 21 043 1000
- E-post: rcteles@outlook.com
-
-
-
-
-
A Coruña, Spania
- Rekruttering
- Hospital Universitario de a Coruna
-
Ta kontakt med:
- Dr Pablo Pinon
- Telefonnummer: +34 981 17 80 00
- E-post: info@jjphospitalaria.com
-
Madrid, Spania
- Rekruttering
- Hospital Clínico San Carlos
-
Ta kontakt med:
- Dr.Luis Nombel
- Telefonnummer: 91 330 30 00
- E-post: gerent.hcsc@salud.madrid.org
-
Valladolid, Spania
- Rekruttering
- Hospital clinico Universitario de Valladolid
-
Ta kontakt med:
- Dr. Filippo Pensotti
- Telefonnummer: +34 983 42 00 00
- E-post: ceim.asva@saludcastillayleon.esjalvarezgo
-
-
-
-
-
Lucerne, Sveits
- Rekruttering
- Luzerner Kantonsspital | Herzzentrum
-
Ta kontakt med:
- Dr.Stefan Toggweiler
- Telefonnummer: 0412051111
- E-post: ifo@luks.ch
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Patients with symptomatic, severe calcified aortic stenosis who are at high surgical risk.
Beskrivelse
Inclusion Criteria:
- Subjects of age≥ 18 years
- Subjects with severe, symptomatic, calcific aortic stenosis who are considered at high risk for surgical aortic valve replacement (AVR).
- Subject can understand the purpose of the clinical investigation, has signed voluntarily the informed consent form and is agreeing to the scheduled follow up requirements.
Exclusion Criteria:
- Pre-existing mechanical heart valve in aortic position
- A known hypersensitivity or contraindication to all anticoagulation /antiplatelet regimens (or inability to be anticoagulated for the index procedure), to nickel or titanium, to nitinol, to dairy products, to polyethylene terephthalate (PET) or contrast media
- Ongoing sepsis, including active endocarditis
- Anatomically not suitable for the VitaFlow Liberty TAV system
- LVEF<20%
- Estimated life expectancy of less than 12 months
- Any medical, social or psychological condition that in the opinion of the Heart Team precludes the subject from receiving transcatheter aortic valve replacement
- Currently participating in another drug or device trial (excluding registries) for which the primary endpoint has not been assessed
- Inability to comply with the clinical investigation follow-up or other clinical investigation requirements
- Patients temporally unable to provide written informed consent (e. g. unconscious emergency patients)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Enarms klinisk undersøkelse
|
Transcatheter Aortic Valve Replacement with VitaFlow Liberty™ Transcatheter Aortic Valve System. Patients will receive transcatheter aortic valve replacement and examinations at the screening, procedure, discharge, and follow-up per local standard of care. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Composite rate of all-cause mortality and stroke with disability
Tidsramme: 12 months post procedure
|
Composite rate of all-cause mortality and stroke with disability |
12 months post procedure
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety outcomes defined by VARC3
Tidsramme: 30 days, 12 months, and 2-5 years post procedure
|
Rate of all-cause mortality, myocardial infarction, stroke, implanted related new and/or worsen conduction disturbances and arrhythmias, new permanent pacemaker implantation, procedure-related or valve-related hospitalization defined by VARC 3. |
30 days, 12 months, and 2-5 years post procedure
|
|
Safety outcomes defined by VARC3
Tidsramme: 30 days and 12 months post procedure
|
Rate of type 2-4 bleeding, major vascular and access-related complications, acute kidney injury (stage 2-4) defined by VARC 3 |
30 days and 12 months post procedure
|
|
Safety outcomes defined by VARC3
Tidsramme: acute procedure (within 24 hours)
|
Rate of other acute procedural and technical valve related complications: conversion to surgery; unplanned use of mechanical circulatory support; implantation of multiple (>1) transcatheter valves during the index hospitalization; valve mal-position |
acute procedure (within 24 hours)
|
|
Device success
Tidsramme: 30 days post implantation
|
Device success defined by VARC 3 |
30 days post implantation
|
|
Device early safety
Tidsramme: 30 days post implantation
|
Device early safety defined by VARC 3 |
30 days post implantation
|
|
Bioprosthesis haemodynamic function
Tidsramme: Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation
|
Bioprosthesis haemodynamic function (assessed by echocardiography) including effective orifice area (cm2). |
Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation
|
|
Bioprosthesis haemodynamic function
Tidsramme: Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation
|
Bioprosthesis haemodynamic function (assessed by echocardiography) including mean transvalvular gradient (mmHg). |
Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation
|
|
Bioprosthesis haemodynamic function
Tidsramme: Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation
|
Bioprosthesis haemodynamic function (assessed by echocardiography) including aortic regurgitation (paravalvular, central and total). |
Discharge (24 hours to 7 days), 30 days,12 months and 2-5 years post implantation
|
|
Bioprosthetic valve dysfunction
Tidsramme: 12 months and 2-5 years post procedure
|
Moderate or severe haemodynamic valve deterioration defined by VARC3 |
12 months and 2-5 years post procedure
|
|
Bioprosthetic valve dysfunction
Tidsramme: 12 months and 2-5 years post procedure
|
Bioprosthetic valve failure defined by VARC3 |
12 months and 2-5 years post procedure
|
|
Bioprosthetic valve dysfunction
Tidsramme: 12 months and 2-5 years post procedure
|
Clinically significant valve thrombosis defined by VARC3 |
12 months and 2-5 years post procedure
|
|
NYHA Classification
Tidsramme: From baseline to discharge (24 hours to 7 days), 30 days, 12 months and 2-5 years post procedure
|
Changes in cardiac function at discharge, 30 days and 12 months and 2-5 years post implantation according to the NYHA Classification Scheme compared to baseline |
From baseline to discharge (24 hours to 7 days), 30 days, 12 months and 2-5 years post procedure
|
|
Rate of Alwide Plus Balloon Catheter pre-dilation success
Tidsramme: During procedure
|
Defined as successful access, delivery and dilation the aortic valve, and retrieval for the AlwideTM Plus balloon catheter |
During procedure
|
|
Alwide Plus Balloon Catheter related adverse-event
Tidsramme: Discharge
|
Discharge
|
|
|
Predictors for the permanent pacemaker implantation
Tidsramme: Baseline or intraprocedure
|
Including but not limited to pre-existing conduction disturbance, implant depth, LVOT calcium volume , post-dilatation |
Baseline or intraprocedure
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Darren Mylotte, MD, Galway University Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- VitaFlow EU-2024
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .